Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...
Streetwise Reports | November 19, 2019 |

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results

Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. San Diego, Calif.-based biopharmaceutical company ACADIA Pharmaceu...
Streetwise Reports | September 10, 2019 |

Protagonist's Shares Nearly Double After Reporting Q1 Earnings and Positive Phase 2 Trial Results

Shares of Protagonist Therapeutics traded higher and reached a new 52-week high price after the company released Q1/20 financial results and positive data from its Phase 2 study of PTG-300 in patients with polycythemia vera, a type of blood cancer. After U.S...
Streetwise Reports | May 11, 2020 |

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. Global biopharmaceutical company Insmed Inc. (INSM:NASDAQ) , which is...
Streetwise Reports | February 4, 2020 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

Reliq Re-establishes Itself as Community Care Technology Leader ...

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes A shift in the industry leads to big new contracts and parabolic stock performance for this small cap. A sweeping new development in what federal...
Streetwise Reports | November 14, 2019 |

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. Ocular Ther...
Streetwise Reports | March 5, 2020 |

Blockchain Holdings Acquires COVID-19 Quarantine Tracker Already in Use in Hong Kong

The company anticipates adoption of the TRACEsafe system by other countries soon. Blockchain Holdings Ltd. (BCX:CSE) announced that it has entered into a binding letter of intent to acquire "100% of the rights and interests in a self-quarantine monitoring...
Streetwise Reports | March 23, 2020 |

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer

An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report. In a May 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that for Nabriva Therapeutics Plc (NBRV:NASDAQ) , "all eyes [are] on [its] Au...
Streetwise Reports | May 16, 2019 |

For Better or Worse? On the Verge of a New Era in Investing

(The Global 7500 aircraft. Image via Bombardier Inc.) If there is one thing that we have learned one year into the COVID-19 pandemic, we must often take things as they come, week by week, especially in a volatile market. It's no April Fool's prank. Each week, w...
Stockhouse Editorial | March 31, 2021 |
1 2 3 4 5 6 7 8 9 10 ...